

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Application Number</i>	10/579,251
				<i>Filing Date</i>	October 20, 2006
				<i>First Named Inventor</i>	Luca Gianni
				<i>Art Unit</i>	1623
				<i>Examiner Name</i>	Jonathan S. Lau
				<i>Attorney Docket Number</i>	13566.105020
Sheet	1	of	1		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Chabner et al., Cancer Chemotherapy and Biotherapy: Principles and Practice, Third Edition, pages 1-16, 2001	
		Forouzesh et al., Internet Archive, Internet Archive Entry for Proc. Am. Soc. Clin. Oncol. ASCO meeting, Abstract 373, June 3, 2001, 32 pages	
		Perotti et al., "Cardiotoxic effects of anthracycline-taxane combinations," Expert Opin Drug Saf, 2(1), 59-71, January 2003	
		PR Newswire, PR Newswire, October 14, 2001, 4 pages	
		Rote Liste 2002 "Doxorubicin," entries 86-056 through 86-062, 2002	
		Slamon et al., "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2", New England Journal of Medicine, 2001, 344(11):783-92	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--